



RECEIVED

AUG 08 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Applicant: Jordan J. N. Tang, Xinli Lin, Gerald Koelsch, and Lin Hong
Serial No: 09/604,608 Art Unit: 1625
Filed: February 18, 2000 Examiner: D. Seaman
For: CATALYTICALLY ACTIVE RECOMBINANT MEMAPSIN AND
METHODS OF USE THEREOF

Assistant Commissioner
for Patents
Washington, D. C. 20231

**POWER OF ATTORNEY BY ASSIGNEE OF THE ENTIRE INTEREST
AND REVOCATION OF PRIOR POWERS**

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabst
Zhaoyang Li
Rivka Monheit

Registration No. 31,284
Registration No. 46,872
Registration No. P-48,731

Please send all correspondence relating to the above-identified patent application to:

Patrea L. Pabst
HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, Suite 2000
Atlanta, Georgia 30309-3400

(404) 817-8473 - Telephone
(404) 817-8588 - Telefax

#4930 P.003/004

RECEIVED

AUG 08 2001

TECH CENTER 1600/2900



The undersigned signatory (whose title is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

By: Larry J. Kennedy
Name: Larry J. Kennedy
Title: Director, Technology Transfer

Date: July 26, 2001

AT&T #472078 v1

RECEIVED
#4930 P.001/001

AUG 08 2001



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
Approved for public use under CFR 1.200(e)(2) (3) (iii), 37 CFR 1.200(e)(2) (3) (iii).
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Jorgen J.N. Tang and Arul K. Ghosh

Application No./Patent No.: 09/306,988 Filed/Issue Date: February 18, 2002

Entitled: **PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE**

Oklahoma Medical Research Foundation, a University

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of an undivided part interest

In the patent application/patent (delineated above) by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at File #00772, Frame 5849, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s) of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.
NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302.8

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Barry J. Kennedy
typed or printed name

Director, Technology Transfer
Title

Statement of Use. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.